Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viemed HealthcareVMD +0.27%89 3-Year EBITDA Growth Rate is 26.60% as of Jun. 2026, which is 30% above its 10-year median of 20.50. GuruFocus rates VMD with a GF Score™ of 89/100 and a GF Value™ of $10.97 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 690 Medical Devices & Instruments companies, Viemed Healthcare ranks better than 73.62% on this metric.
During the past 12 months, Viemed Healthcare's average EBITDA Per Share Growth Rate was 16.40% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 26.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 11.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Viemed Healthcare was 99.70% per year. The lowest was 0.30% per year. And the median was 20.50% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Viemed Healthcare 3-Year EBITDA Growth Rate Related Terms
VMD vs OFIX, VREX, SI: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Viemed Healthcare's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viemed Healthcare 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Viemed Healthcare's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Viemed Healthcare's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 26.60% mean?
Viemed Healthcare (VMD) has a 3-Year EBITDA Growth Rate of 26.60% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Viemed Healthcare and its competitors. This is 30% above median its historical median of 20.50. Over the past decade, Viemed Healthcare's 3-Year EBITDA Growth Rate has ranged from 0.30 to 99.70. According to the industry distribution chart, Viemed Healthcare ranks #182 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 26.4%.
Is Viemed Healthcare's 3-Year EBITDA Growth Rate too high?
Viemed Healthcare's current 3-Year EBITDA Growth Rate of 26.60% is 30% above median its 10-year median of 20.50. Over the past 10 years, this metric has ranged from a low of 0.30 to a high of 99.70. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. Viemed Healthcare's value of 26.60% is 224.4% above this industry median. Based on the distribution chart, Viemed Healthcare ranks #182 out of 690 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Viemed Healthcare has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Viemed Healthcare's 3-Year EBITDA Growth Rate compare to OFIX and VREX?
According to the Medical Devices & Instruments industry distribution chart, Viemed Healthcare ranks #182 out of 690 companies for 3-Year EBITDA Growth Rate. This puts Viemed Healthcare in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.20. Viemed Healthcare's value of 26.60% is 224.4% above this benchmark. Historically, Viemed Healthcare's own 3-Year EBITDA Growth Rate has ranged from 0.30 to 99.70 over the past decade. While the company's 10-year median is 20.50 vs. the industry median of 8.20, Viemed Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viemed Healthcare's current 3-Year EBITDA Growth Rate of 26.60% is 224.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Viemed Healthcare and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viemed Healthcare's current 3-Year EBITDA Growth Rate is 26.60%, which is 30% above median its own 10-year median of 20.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viemed Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Viemed Healthcare (VMD) is currently considered Modestly Undervalued. The stock's GF Value™ is $10.97, compared to a current price of $9.20 — trading 16.1% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 26.60%, which is 30% above median its 10-year median of 20.50 and 224.4% above the Medical Devices & Instruments industry median of 8.20. Viemed Healthcare's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Viemed Healthcare (VMD), the current 3-Year EBITDA Growth Rate is 26.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viemed Healthcare (VMD) Overvalued in 2026?
Based on GuruFocus' analysis, Viemed Healthcare stock appears to be undervalued.
The current stock price of $9.20 is trading 16.1% below its estimated GF Value™ of $10.97.
GuruFocus considers Viemed Healthcare to be Modestly Undervalued.
Key valuation signals for VMD:
3-Year EBITDA Growth Rate: 26.60% (30% above median its 10-year median of 20.50)
GF Value™: $10.97 vs. price of $9.20 (16.1% below fair value)
Industry Position: 224.4% above the Medical Devices & Instruments median (#182 of 690)
No single metric tells the full story. See the VMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viemed Healthcare Inc is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services. The Company's primary service offerings focus on effective in-home treatment, with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. The company generates the majority of its revenue from medical equipment rental, sales, and supply.
89GF Score
Get the complete analysis for VMD
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VMD has been successfully added to your 
